Cooperative Agreement U19AI181587
Award Date
8/20/24
Completion Date
5/31/29
Dollars Obligated
$702K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Cooperative Agreement
Place of Performance
Great Britain, United Kingdom
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $700,288 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of South Florida (USF) to conduct phenotype-based screens and functional genomics research to identify genetic factors associated with gametocyte development in Plasmodium falciparum, the major global cause of malaria. The project, running from November 2024 to October 2029, will use a random piggyBac mutagenesis approach to...
This $184,109 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to investigate the role of inhibitory immune receptors in regulating monocyte and T cell functions during subclinical malaria infections in children. The research aims to define the immunoregulatory phenotypes of monocytes and T cells, determine monocyte function, and perform transcriptomic analysis to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,104,050 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The grant will fund research to investigate the molecular mechanisms by which the Plasmodium falciparum malaria parasite's secreted histidine-rich protein II (HRPII) impairs the function of human neutrophils, a critical component of the immune response. The goal is to elucidate...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $800,972 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) to conduct research on profiling malarial lipid biosynthesis and acyl-coenzyme A synthetase activities. The key products and services to be delivered through this 2-year award (7/2/2024 - 5/31/2026) include: Developing a new "fatty acid alkyne...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $587,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to optimize the structural features of the antimalarial drug candidate ELQ-596 for once-monthly oral prophylaxis in humans. The project aims to develop a next generation of ELQ compounds with improved intrinsic anti-plasmodial activity, enhanced efficacy in animal models, and...
This federal Project Grant award R01AI183599 in the amount of $1,553,810 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to evaluate a genomic surveillance approach for monitoring the emergence of artemisinin resistance in Plasmodium falciparum malaria parasites in Africa. The key objectives are to: 1) identify parasite genetic loci under selection over time...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...
The federal Project Grant award R01AI182253, with a total funding amount of $708,202.00, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this 5-year grant is to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The research activities will be conducted by the prime awardee,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $699,814 to Florida International University (FIU) to study the molecular mechanisms of Plasmodium-Anopheles midgut interactions and develop novel transmission-blocking vaccine approaches for malaria. The key objectives are to functionally characterize mosquito and parasite proteins involved in midgut invasion,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $479,204 to the University of Maryland, Baltimore to conduct research on parasite variant surface antigens and their role in severe malaria. The research aims to identify parasite genes associated with severe disease, which could inform vaccine and drug development. Key aspects include: Sequencing variant surface antigen transcripts...